Ramón
García Sanz
Profesor Titular de Universidad
Universitat de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat de Barcelona (26)
2024
2023
-
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors
Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
-
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
Seminars in Hematology
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067
-
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Blood Advances
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Genetically determined telomere length and multiple myeloma risk and outcome
Blood Cancer Journal, Vol. 11, Núm. 4
2019
-
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Leukemia
-
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811
2018
2017
-
Identification of miRSNPs associated with the risk of multiple myeloma
International Journal of Cancer, Vol. 140, Núm. 3, pp. 526-534
2015
-
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length
International Journal of Cancer, Vol. 136, Núm. 5, pp. E351-E358
-
Type 2 diabetes-related variantsinfluence the risk of developing multiple myeloma: Results from the IMMEnSE consortium
Endocrine-Related Cancer, Vol. 22, Núm. 4, pp. 545-559
2014
-
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations - An extensive replication of the associations from the candidate gene era
Cancer Epidemiology Biomarkers and Prevention, Vol. 23, Núm. 4, pp. 670-674